晚期胸腺癌19例临床病理与预后分析  

Clinicopathological Features and Prognosis of 19 Cases with Advanced Thymic Carcinoma

作　　者：王利欢[1,2] 李月敏[1] 张玉海[1] 夏火生[1] 武勇[1] 孟少林 冯小兵[1] 宋乐乐[1] 

机构地区：[1]解放军第309医院,北京100091 [2]河北北方学院研究生部,河北张家口075000

出　　处：《肿瘤学杂志》2015年第3期228-232,共5页Journal of Chinese Oncology

摘　　要：[目的]探讨晚期胸腺癌的临床病理特点及预后。[方法]回顾性分析19例经病理或细胞学检查证实的晚期胸腺癌患者的临床病理资料。[结果]鳞癌占全部患者的63.2%。全组患者3年生存率为46.7%。手术患者与非手术患者的3年生存率分别为83.3%和22.2%(P<0.05)。完整切除与未完整切除(包括部分切除和手术探查)的患者3年生存率分别为100.0%和60.0%(P>0.05)。放疗患者与非放疗患者的3年生存率分别为50.0%和33.3%(P>0.05)。Ⅲ期与Ⅳ期患者的3年生存率分别为71.4%和25.0%(P>0.05)。高分化癌(鳞癌)和低分化癌(神经内分泌癌、未分化癌)的3年生存率分别是50.0%和42.9%(P>0.05)。[结论 ]鳞癌是最常见的胸腺癌病理亚型。晚期胸腺癌患者应尽可能完整手术切除,术后辅以放化疗。手术切除、WHO病理分型影响胸腺癌患者预后。[Purpose]To investigate the clinicopathological features and prognosis of advanced thymic carcinoma. [MethodslThe data from 19 patients with advanced thymic carcinoma pathologically or cytologically confirmed were analyzed retrospectively. [ Results] Squamous cell carcinoma accounted for 63.2% of the total cases. The overall 3-year survival rate was 46.7%. 3-year survival rate for patients with surgical resection and without resection was 83.3% and 22.2% （P〈0.05）respectively. 3-year survival rate for complete resection and non-complete resection patients was 100.0% and 60.0%（P〉0.05）respectively. 3-year survival rate for patients with radiotherapy and without radiotherapy was 50.0% and 33.3% （P〉0.05）respectively. 3-year survival rate for stage III and stage IV patients was 83.3% and 22.2%（P〉0.05）respectively. 3-year survival rate for low and high grade groups was 50.0% and 42.9% （P〉0.05）respectively. [Conclusion lThe most common histological subtype is squamous cell carcinoma. The main treatment modality for advanc, ed thymic carcinoma is complete resection,followed by chemoradiotherapy. Surgery and WHO pathologic typing influence the prognosis of thymic carcinoma patients.

关 键 词：胸腺肿瘤 临床病理学 综合治疗 预后 外科手术 

分 类 号：R736.3[医药卫生—肿瘤]